Presage Biosciences raises $13M, inks collaborations with Merck and Maverick to test cancer drugs using CIVO

Seattle-based Presage Biosciences raised $13 million in its first venture round, bringing total equity to $35 million, and announced new collaborations with Merck and Maverick Therapeutics to use its CIVO platform for testing cancer drugs in human tumors. The CIVO device enables micro-dosing and biomarker tracking in phase 0 trials, aiming to improve preclinical screening and reduce failures in costly phase I trials.